With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Barbara Engelhardt moves her computational and statistics lab to Gladstone
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The medicine is now approved for eight indications across five different types of cancer in China.
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
PPH is associated with almost 20 per cent of maternal mortality in India
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
